Article Text
Statistics from Altmetric.com
OpenUrlCrossRefPubMedWeb of Science
Q Does adding sarcosine or D-serine to risperidone improve symptoms in people with acute phase schizophrenia?
METHODS
Design:
Randomised controlled trial.
Allocation:
Concealed.
Blinding:
Double blind.
Follow up period:
Six weeks.
Setting:
Two hospital inpatient units, Taiwan, from January 2000 to July 2003.
Patients:
Sixty five people aged 18–60 years with acute exacerbation of DSM-IV schizophrenia (45% female). Exclusions: baseline Positive and Negative Syndrome Scale (PANSS) total score <60; abnormal urine, blood, biochemical, or electrocardiography results; substance abuse or dependence; smoker; received atypical antipsychotic; contrainidication to antipsychotics; or received depot antipsychotic in previous six months.
Intervention:
D-serine (2 g/day) plus risperidone (titrated to 6 mg/day); sarcosine (2 g/day) plus risperidone; placebo plus …
Footnotes
For correspondence: Guochuan E Tsai, Department of Psychiatry, Harbor-UCLA Medical Center, 1000 W Carson Street, Torrance, CA 90509, USA; etsai{at}labiomed.org
Sources of funding: National Science Council, National Health Research Institutes and China Medical University, Taiwan, and the National Alliance for Research on Schizophrenia and National Institute of Mental Health, USA.